Prestige Consumer Q1FY27 Results: Revenue rises 6.5% to $266 million
- Revenue increased 6.5% YoY to $265.7 million in Q1FY27
- Adjusted EPS rose to $0.98 from $0.95 in the prior year
- Full-year revenue guidance raised to $1.29-$1.315 billion due to acquisitions
- Adjusted free cash flow reached a quarterly record of $83.7 million
- Gross margin declined 120 bps YoY to ~55%, but guided to >57% for FY27
*this image is generated using AI for illustrative purposes only.
Prestige Consumer Healthcare Inc reported first-quarter fiscal 2027 revenue of $265.7 million, a 6.5% increase year-over-year, driven by strong performance in gastrointestinal (GI) and skincare categories.
The company raised its full-year revenue guidance to $1.29 billion to $1.315 billion, up from previous estimates, primarily due to the recent acquisitions of Breathe Right and Locorium Health. Organic growth expectations remain unchanged at 1% to 3%. Adjusted diluted EPS rose to $0.98 from $0.95 in the prior year period, while adjusted free cash flow hit a quarterly record of $83.7 million.
Segment Performance and Operational Highlights
North America segment revenues grew 4.2% organically, excluding foreign currency effects and acquisition contributions. Growth was led by GI brands Dramamine and Fleet, alongside strong dermatological sales from Compound W. These gains offset supply-constrained declines in Clear Eyes eye care products.
International segment revenues declined 2.1% organically, attributed to timing in distributor orders rather than consumption weakness. Management reaffirmed the long-term organic growth target of 5% or more for this segment for the full fiscal year.
| Metric | Q1FY27 | Q1FY26 | Change |
|---|---|---|---|
| Revenue | $265.7 million | $249.5 million | +6.5% |
| Adjusted EPS | $0.98 | $0.95 | +3% |
| Adjusted Gross Margin | ~55% | ~56.2% | -120 bps |
| Adjusted Free Cash Flow | $83.7 million | N/A | Record |
Acquisition Impact and Guidance Update
The integration of Breathe Right is nearly complete, with the portfolio expected to generate approximately $200 million in annual revenue. Locorium Health contributes an estimated $40 million annually. Together, these acquisitions are projected to add over 20% to Prestige’s annualized revenue base.
Management noted that the increase in full-year guidance is entirely driven by these acquisitions, which are expected to contribute approximately $190 million in revenue for fiscal 2027. Adjusted gross margin guidance for the full year has been revised upward to just over 57%, reflecting the accretive margins of the new assets.
What the Numbers Show
A divergence exists between top-line growth and margin stability. While revenue rose 6.5%, adjusted gross margin contracted by 120 basis points to approximately 55%. Management attributed this decline to higher transportation costs and product mix shifts. However, the inclusion of higher-margin acquired businesses is expected to reverse this trend, with full-year adjusted gross margin guided to exceed 57%. Additionally, record free cash flow of $83.7 million highlights the efficiency of working capital management despite rising interest expenses from acquisition-related debt.
How will the integration of Breathe Right and Locorium Health specifically impact Prestige's debt leverage ratios and interest expense trajectory in upcoming quarters?
Can the company sustain the projected full-year gross margin expansion to over 57% if transportation cost inflation persists beyond the current quarter?
What specific strategic initiatives is management implementing to reverse the 2.1% organic decline in international revenues and meet the 5%+ long-term growth target?
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
